Search results
Results from the WOW.Com Content Network
Asherman's syndrome (AS) is an acquired uterine condition that occurs when scar tissue forms inside the uterus and/or the cervix. [1] It is characterized by variable scarring inside the uterine cavity, where in many cases the front and back walls of the uterus stick to one another.
An important risk factor for placenta accreta is placenta previa in the presence of a uterine scar. Placenta previa is an independent risk factor for placenta accreta. Additional reported risk factors for placenta accreta include maternal age and multiparity, other prior uterine surgery, prior uterine curettage, uterine irradiation, endometrial ablation, Asherman syndrome, uterine leiomyomata ...
Asherman has published dozens of medical articles. Among other things, he described a syndrome that bears his name, Asherman's Syndrome, which includes scarring and infection in the uterus due to curettage, which was first described by a German doctor ( Heinrich Fritsch ) in 1894 but was characterized following two articles by Asherman in 1948 ...
The Mayo Clinic diet, a program that adheres to this notion, was developed by medical professionals based on scientific research, so you can trust that this program is based on science, and not ...
Vaginal stenosis is an abnormal condition in which the vagina becomes narrower and shorter due to the formation of fibrous tissue. [1] [2] Vaginal stenosis can contribute to sexual dysfunction, dyspareunia and make pelvic exams difficult and painful. [1]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate
Post-maturity syndrome is the condition of a baby born after a post-term pregnancy, first described by Stewart H. Clifford in 1954. [1] Post-maturity refers to any baby born after 42 weeks gestation, or 294 days past the first day of the mother's last menstrual period. Less than 6 percent of all babies are born after this time. [2]
It helped reduce scarring by at least two stages in over a third of the patients taking a higher dose, and 31% on the lower dose, versus 3% of patients on placebo, Akero said.